Olorofim

Olorofim

Olorofim

Chemical compound

Olorofim (F901318) is an experimental antifungal drug being developed for invasive mold infections.[1][2] If approved it would be a first-in-class medication (for the orotomide class). In 2023, the FDA decided not to approve the drug and to request more data about the safety of the drug.[3] Olorofim does not inhibit growth of Candida species.[2]

Quick Facts Clinical data, Other names ...

References

  1. [1]
    Neoh, Chin Fen; Jeong, Wirawan; Kong, David CM; Slavin, Monica A (2023). "The antifungal pipeline for invasive fungal diseases: what does the future hold?". Expert Review of Anti-infective Therapy. 21 (6): 577–594. doi:10.1080/14787210.2023.2203383. PMID 37057677. S2CID 258135111.
  2. [2]
    Wiederhold, Nathan P. (2020). "Review of the Novel Investigational Antifungal Olorofim". Journal of Fungi. 6 (3): 122. doi:10.3390/jof6030122. ISSN 2309-608X. PMC 7557671. PMID 32751765.
  3. [3]
    "FDA Passes on Olorofim Despite Critical Need for Antifungals". Medscape.
Share this article:

This article uses material from the Wikipedia article Olorofim, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.